NCT03868774

Brief Summary

Repetitive transcranial magnetic stimulation has appeared a new non-invasive antidepressant method, which implies non-convulsive focal stimulation of the prefrontal cortex of the brain through a time varying magnetic field. The method is associated with minimal side effects limited to local discomfort and especially no impact on cognitive function. The method has been approved for the treatment of depression in Canada, USA and a couple of European countries. The department for Affective Disorders, Aarhus University Hospital has used rTMS as add-on to conventional antidepressant treatment in the outpatient clinic since 2015. A single treatment course covers 20 sessions given on 20 consecutive days. The demand for daily treatment and attendance for 20 days is resource demanding for both the patient and the clinic. In consequence the investigators want to examine the antidepressant effect of an accelerated stimulus model comparing the outcome of the standard model ( 20 days) with a treatment model covering the same number of stimuli given within one week.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Sep 2019

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 7, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 11, 2019

Completed
6 months until next milestone

Study Start

First participant enrolled

September 1, 2019

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2019

Completed
Last Updated

August 19, 2019

Status Verified

August 1, 2019

Enrollment Period

Same day

First QC Date

March 7, 2019

Last Update Submit

August 15, 2019

Conditions

Keywords

treatment

Outcome Measures

Primary Outcomes (1)

  • The Hamilton 17 item scale score for depression

    A semistructured interview. On the basis of a systematic registration of well defined depressive symptoms through the preceding 3 days a total 17 item score and af 6-item subscale score expressing the degree of depression is calculated. The score is positively correlated to the degree af depression, Remission is defined as a total score after termination of treatment of \>= 8, response is defined by \>= 50% decrease in the total 17 item score during the treatment period

    up to 4 weeks

Secondary Outcomes (1)

  • cognitive function

    1 and 4 weeks

Study Arms (2)

rTMS standard

ACTIVE COMPARATOR

Low frequency (1 Hz), rTMS 20 sessions given on 20 consecutive days ( except weekends)

Procedure: repetitive transcranial magnetic stimulation

rTMS accelerated model

ACTIVE COMPARATOR

Low frequency ( 1 Hz), right prefrontal transcranial magnetic stimulation. 20 sessions given on 5 consecutive days ( 4 sessions each day)

Procedure: repetitive transcranial magnetic stimulation

Interventions

rTMS is a new non-invasive antidepressant method, which implies non-convulsive focal stimulation of the prefrontal cortex of the brain through a time varying magnetic field.

rTMS accelerated modelrTMS standard

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Moderate-severe uni- and bipolar depression according to the International Classification of Diseases (ICD-10)
  • A Hamilton scale score (HDS-17) of ≥ 18 and/or a sub-scale (HDSS) score of ≥ 9 within 24-48 hours before the first treatment

You may not qualify if:

  • Organic brain disease.
  • Epileptic seizure \< 2 years
  • Patients with implanted metal parts in the brain or chest
  • Patients with pacemaker
  • Medical diseases with cerebral impact
  • Serious suicidal danger

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Depression

Interventions

Transcranial Magnetic Stimulation

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehavior

Intervention Hierarchy (Ancestors)

Magnetic Field TherapyTherapeutics

Study Officials

  • Poul Erik Buchholtz, MD

    Department of Depression and Anxiety

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Project collaborators examining the degree of depression during intervention are blinded to the type of treatment
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: comparing the antidepressant effect of a standard rTMS model with an accelerated treatment model
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
senior researcher

Study Record Dates

First Submitted

March 7, 2019

First Posted

March 11, 2019

Study Start

September 1, 2019

Primary Completion

September 1, 2019

Study Completion

September 1, 2019

Last Updated

August 19, 2019

Record last verified: 2019-08

Data Sharing

IPD Sharing
Will not share